Oncostatin M Antagonists Inhibit Tumor Detachment
Solution Overview
Problem
Current treatments for cancer metastasis, particularly for prostate and breast cancer, are inadequate in inhibiting tumor cell detachment, proliferation, and metastasis, as they do not effectively target the signaling molecules implicated in these processes.
Innovation Solution
Administration of OSM antagonists, including small molecules, antibodies, and nucleic acid molecules, that block OSM interaction with its receptors, thereby inhibiting signaling pathways and reducing cytokine and matrix metalloproteinase synthesis, to prevent tumor cell detachment and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cancer metastasis are used, then general cancer therapy is provided, but they are inadequate in inhibiting tumor cell detachment, proliferation, and metastasis
Solution Approach 1:
The patent changes the molecular target parameter from general cancer therapy to specifically targeting OSM signaling pathway. By identifying and targeting the OSM-cytokine signaling pathway that is upregulated in metastatic cancer cells, the treatment achieves superior efficacy in inhibiting tumor cell detachment, proliferation, and metastasis compared to conventional therapies.
Solution Approach 2:
The patent introduces OSM antagonists as intermediary molecules that block the interaction between OSM and its receptors. These antagonists serve as mediators that interfere with the signaling pathway, preventing the transmission of metastatic signals from OSM to the cellular machinery that executes detachment and proliferation.
2Reliability
If OSM antagonists are administered to block OSM interaction with receptors, then tumor cell detachment and metastasis are reduced, but the complexity of the treatment increases
Solution Approach 1:
The patent extracts and isolates the specific OSM signaling pathway from the complex network of cancer-related signaling molecules. By focusing treatment exclusively on blocking OSM-receptor interaction, the approach simplifies the therapeutic strategy while maintaining high efficacy in preventing tumor cell detachment and metastasis.
Solution Approach 2:
The patent segments the cancer treatment approach by specifically targeting the OSM pathway rather than using broad-spectrum cancer therapies. This segmentation allows for more precise and effective inhibition of metastatic processes while potentially reducing off-target effects and treatment complexity.
Data Source
AI summary
A method of treating cancer or metastasis is provided involving administering at least one oncostatin M (OSM) antagonist to a subject, wherein the subject has been diagnosed with cancer. Administration of an OSM antagonist such as a small molecule pharmaceutical is provided as well as an anti-OSM antibody, an anti-OSM aptamer, and an OSM mRNA antagonist. The OSM antagonists were found to inhibit or prevent tumor cell detachment, progression, proliferation and metastasis in several cancer types.